title: Fractionated stereotactic radiotherapy for bilateral vestibular schwannomas associated with neurofibromatosis type 2: early experiences in Ramathibodi Hospital.
abstract: OBJECTIVE
  To evaluate the rates of tumor control and useful hearing preservation in patients with bilateral vestibular schwannomas (VSs) associated with neurofibromatosis type 2 (NF-2) treated with fractionated stereotactic radiotherapy (FSRT).
  
  
  METHODS
  From August 1998--December 2002 there were 5 patients with NF-2 who underwent FSRT (Linac-based system) for bilateral CP angle tumors. Median age was 28 (18-47) years. Median tumor volume was 5.4 (2.2-9.4) cc. Eight lesions received a marginal dose of 44.2-59.9 (median = 46.2) Gy in 25-33 fractions. The other 2 lesions received 4.4 and 4.9 Gy/fraction for 6 fractions in 3 and 2 weeks. Median follow-up was 19 (14-44) months.
  
  
  RESULTS
  Radiographic and clinical tumor control rate was 90%. One lesion progressed at 7 months after FSRT and was completely resected Of the 5 lesions with Gardner-Robertson class I-II hearing before FSRT 2 (40%) retained useful hearing at the last follow-up. One patient had left facial spasm at 10 months after FSRT which gradually improved. No patient had facial palsy, facial numbness or pain.
  
  
  CONCLUSIONS
  FSRT provided good tumor control and hearing preservation rate in NF-2 patients with minimal morbidity. However, a longer follow-up is needed to evaluate long term results.
authors.affiliation: Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand.
authors.forename: Mantana
authors.initials: M
authors.lastname: Dhanachai
authors.forename: Veerasak
authors.initials: V
authors.lastname: Theerapancharoen
authors.forename: Jiraporn
authors.initials: J
authors.lastname: Laothamatas
authors.forename: Chanchai
authors.initials: C
authors.lastname: Jariengprasert
authors.forename: Puangtong
authors.initials: P
authors.lastname: Kraiphibul
authors.forename: Pornpan
authors.initials: P
authors.lastname: Yongvithisatid
mesh_terms: D000293:Adolescent; D000328:Adult; D018450:Disease Progression; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016518:Neurofibromatosis 2 / Q000150:complications*; D009464:Neuroma, Acoustic / Q000532:radiotherapy*; D013238:Stereotaxic Techniques; D016896:Treatment Outcome